These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29245078)

  • 1. Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.
    Yan J; Wu X; Yu J; Yu H; Xu T; Brown KM; Bai X; Dai J; Ma M; Tang H; Si L; Chi Z; Sheng X; Cui C; Kong Y; Guo J
    Eur J Cancer; 2018 Jan; 89():90-101. PubMed ID: 29245078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binimetinib for the treatment of NRAS-mutant melanoma.
    Queirolo P; Spagnolo F
    Expert Rev Anticancer Ther; 2017 Nov; 17(11):985-990. PubMed ID: 28851243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
    Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK inhibitors for the treatment of NRAS mutant melanoma.
    Sarkisian S; Davar D
    Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Schadendorf D; Ascierto PA; Arance A; Dutriaux C; Di Giacomo AM; Rutkowski P; Del Vecchio M; Gutzmer R; Mandala M; Thomas L; Demidov L; Garbe C; Hogg D; Liszkay G; Queirolo P; Wasserman E; Ford J; Weill M; Sirulnik LA; Jehl V; Bozón V; Long GV; Flaherty K
    Lancet Oncol; 2017 Apr; 18(4):435-445. PubMed ID: 28284557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
    Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
    Malka-Mahieu H; Girault I; Rubington M; Leriche M; Welsch C; Kamsu-Kom N; Zhao Q; Desaubry L; Vagner S; Robert C
    Cell Cycle; 2016 Sep; 15(18):2405-9. PubMed ID: 27533468
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
    Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
    Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
    Vogel CJ; Smit MA; Maddalo G; Possik PA; Sparidans RW; van der Burg SH; Verdegaal EM; Heck AJ; Samatar AA; Beijnen JH; Altelaar AF; Peeper DS
    Pigment Cell Melanoma Res; 2015 May; 28(3):307-17. PubMed ID: 25728708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of NRAS-mutant melanoma.
    Johnson DB; Puzanov I
    Curr Treat Options Oncol; 2015 Apr; 16(4):15. PubMed ID: 25796376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.
    Rebecca VW; Alicea GM; Paraiso KH; Lawrence H; Gibney GT; Smalley KS
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1154-8. PubMed ID: 25130256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.
    Vu HL; Aplin AE
    Mol Cancer Res; 2014 Oct; 12(10):1509-19. PubMed ID: 24962318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
    Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
    Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.
    Cai W; Nguyen MQ; Wilski NA; Purwin TJ; Vernon M; Tiago M; Aplin AE
    Cancer Res; 2022 Jul; 82(14):2625-2639. PubMed ID: 35657206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
    Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
    Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
    Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
    Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.
    Matter AV; Micaletto S; Urner-Bloch U; Dummer R; Goldinger SM
    Oncologist; 2020 Nov; 25(11):e1593-e1597. PubMed ID: 32886824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.